CLL

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

ARCTIC
Type: A phase II randomised two arm study
Eligibility: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with

FC, mitoxantrone and low dose rituximab (FCM-miniR)

Study details: A radomiised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leykaemia (CLL) to compare fludarabine, cyclophosphamide and ritmuximab (FCR) with FC, mitoxantrone and low dose Rituximab (FCM-miniR).To compare the complete response (CR) rates as defined by IWCLL criteria in each treatment group. To assess the rete of eradication of detectable minimal residual disease (MRD) following treatment with FCR or FCM-miniR
CLL 210 (pending)
Type: A phase II trial of Alemtuzumab, Dexamethasone and Lenalidomide followed by randomisation to Lenalidomide maintenance versus no further treatment for the high-risk CLL (NCRI CLL210)
Eligibility: Progressive marrow failure as manisfested by the development of, or worsening of, anaemia and/or thrombocytopenia. Massive or progressive or symptomatic Splenomegaly. Massive or progressive or symptomatic Lymphadenopathy. Progressive Lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months from a baseline value of at least 30×109/1 and not due to causes other than CLL.
Study details: The CLL210 trial will investigate the safety and efficacy of combination induction therapy with Alemtuzumab, Dexamethasone and Lenalidomide in patients with high-risk CLL. In addition to asking an induction question, the trial will also examine value of continuing the Lenalidomide as post-induction maintenance for patients who achieve a CR or PR.
PICLLe
Type: Phase 1 study
Eligibility: A study of olaparib in relapsed and refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia and Mantle Cell Lymphoma
Study details: Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and replased/refractory patients with T-Prolymphocytic Leukaemia and Mantle Cell Lymphoma.